The antiviral lectins griffithsin (GRFT), cyanovirin-N (CV-N), and scytovirin (SVN), which inhibit several enveloped viruses, including lentiviruses, were examined for their ability to inhibit entry mediated by Env proteins of delta-and gammaretroviruses. The glycoproteins from human T-cell leukemia virus type 1 (HTLV-1) were resistant to the antiviral effects of all three lectins. For gammaretroviruses, CV-N inhibited entry mediated by some but not all of the envelopes examined, whereas GRFT and SVN displayed only little or no effect.
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T
he surface (SU) domain of retroviral Env proteins plays a critical role in binding and entry into target cells. These proteins are always glycosylated and, for most retroviruses, N-linked glycans are responsible for a substantial portion of the molecular mass of SU. High-mannose glycans are attached to an asparagine residue within a conserved motif (Asn-X-Ser/Thr) as the protein is synthesized. Subsequently, a portion of these oligosaccharides is trimmed and remodeled by cellular enzymes; the remainder is not modified and thus retains terminal mannose residues. As a result, the mature SU glycoprotein can have three different types of oligosaccharide structures: high-mannose glycans (with terminal mannose residues), complex glycans (with terminal sialic acid residues), or hybrid glycans (with both types of residues).
The high-mannose form of N-linked glycans is also present on glycoproteins of other enveloped viruses but is rarely found on proteins on human cells (1) . Thus, these represent a target for antiviral therapies. Lectins that specifically bind to high-mannose glycans on the viral envelopes have been shown to inhibit replication of human immunodeficiency virus (HIV) (2-7) as well as other enveloped viruses, including influenza virus (8) , Ebola virus (9), Marburg virus (10), severe acute respiratory syndrome coronavirus (11), hepatitis C virus (12), herpesvirus 6 (13), and measles virus (13) .
Three lectins previously shown to inhibit HIV are cyanovirin-N (CV-N), griffithsin (GRFT), and scytovirin (SVN) (4, 6, 14) . All three have been produced and purified as recombinant proteins and shown to inhibit in vitro replication of many strains of HIV-1 (7, (15) (16) (17) (18) (19) . In addition, CV-N has been shown to inhibit in vivo transmission of simian HIV (SHIV) when used as a topical microbicide (20) (21) (22) .
Although several studies have examined the antiviral effect of these lectins on lentiviruses, little is known about the effects on members of other genera of retroviruses. Here, the effect of GRFT, CV-N, and SVN on the envelope (Env) proteins of deltaretroviruses and gammaretroviruses was examined. Virions pseudotyped with envelopes from these two genera of retroviruses were generated using murine leukemia virus (MLV)-based retroviral vectors as described previously (23) . The effect of GRFT, CV-N, and SVN on the titers of these retroviral vectors was then determined. Vectors pseudotyped with the fusion (F) and hemagglutinin-neuraminidase (HN) glycoproteins of the mumps virus (MuV F and HN), which have high-mannose glycans (24) , and with the G protein of vesicular stomatitis virus (VSV-G), which has complex rather than high-mannose glycans (25, 26) , were used as a positive control and a negative control, respectively. None of the three lectins reduced the titers of the viruses pseudotyped with the Env protein of the human deltaretrovirus human T-cell leukemia virus type 1 (HTLV-1) or HTLV-2 (Fig. 1A) . This was also true for the virus pseudotyped with the Env protein from gibbon ape leukemia virus (GaLV) (Fig. 1B) .
In contrast, CV-N was able to markedly inhibit entry mediated by viruses pseudotyped with the envelope proteins from feline leukemia virus (FeLV) (Fig. 1B, left panel) . This was true for the envelopes of both subgroup A viruses (FeLV-A), which are present in all primary isolates and are horizontally transmitted (27, 28) , and subgroup B viruses (FeLV-B), which are associated with thymic lymphomas and other diseases. Unlike with CV-N, treatment with either GRFT or SVN had only a minor effect on the titers of the vectors pseudotyped with FeLV Env (Fig. 1B , middle and right panels). CV-N was also able to markedly inhibit envelopes from representatives of four types of MLV gammaretroviruses (ecotropic, amphotropic [Ampho], polytropic, and xenotropic), while GRFT and SVN had little effect (Fig. 1C) . The inhibitory effect at different concentrations of CV-N observed for MLV Envs was similar to that observed for FeLV Envs but not to that observed for ecotropic Moloney MLV (MoMLV), for which inhibition was observed only at higher concentrations of CV-N ( dotyped with different Env proteins were generated, and the viruses were exposed to target cells in the presence of the lectins purified as described previously (7, 16, 18) or to an unrelated 24-aa peptide (ACTH; GenScript RP11303), which was used as a negative control. Titers were determined as described previously (23) . Due to differences in the receptors expressed by different cell lines, the following cell lines were used in these experiments for the indicated viral envelopes: The effect of CV-N was also tested on Env of koala retrovirus (KoRV), which is closely related to GaLV. Since the titers of vectors pseudotyped with KoRV in this vector system were too low to measure the effect of this lectin (data not shown), replicationcompetent chimeric viruses carrying the KoRV env gene were used.
KoRV Env, like GaLV Env, was resistant to CV-N inhibition, while CV-N potently inhibited amphotropic clone 4070 (Ampho 4070) in a dose-dependent manner (Fig. 1D) , consistent with what was observed for the single-round infections.
The ability of CV-N to block both the initial infection and the cell-to-cell spread of an infectious gammaretrovirus was exam- ined using FeLV-A, believed to be the primary agent of cat-to-cat spread in nature (28) . Infections performed in the presence of CV-N at concentrations of 1 g/ml or greater dramatically reduced the level of FeLV-A infection in these cultures, while GRFT did not have a significant effect (Fig. 1E ).
In studies with lentiviruses, CV-N has been shown to inhibit HIV at an early stage of infection. CV-N directly binds to the SU domain (gp120) and blocks entry by interfering with essential interactions between SU and receptors on the target cells (4, 7, 29) . To determine whether CV-N functioned in a similar manner in gammaretroviruses susceptible to inhibition, we compared the effects of adding CV-N at various times relative to the time of exposure of the virus to the target cells. Adding CV-N prior to, simultaneously with, or within 15 min of exposure to viral vectors reduced the titer by more than 20-fold ( Fig. 2A) . In contrast, addition of CV-N at later times after exposure had a less dramatic effect on reducing titers. As expected, addition of a negative-control peptide (adrenocorticotropic hormone [ACTH]) did not have any significant effect on the titers at any time point (Fig. 2A) . These observations are consistent with the hypothesis that, as has been shown to be the case when CV-N blocks infection of cells by HIV (4, 7, 29) , CV-N decreases the titers of these vectors by preventing binding and fusion with the target cells during the initial stages of infection.
To verify that CV-N directly binds to the SU domain via the mannose residues, in vitro binding assays were performed using a highly purified recombinant protein (SU-His 6 ) (30) . First, to validate that SU-His 6 and SU present on viral particles bound to target cells in a similar manner, the ability of SU-His 6 to block infection with pseudotyped vectors was determined. Incubation of target cells with the purified SU protein reduced the titers of the vectors pseudotyped with the same Env protein (xenotropic-MLV-related virus [XMRV]) but not of vectors pseudotyped with an unrelated Env protein (VSV-G) (Fig. 2B) , indicating that purified SU and the SU protein on the virions bound to the same receptors. Next, characterization of CV-N-SU interactions using this purified SU protein by enzymelinked immunosorbent assay (ELISA) (4) revealed that the lectin specifically bound to SU in a CV-N concentration-dependent manner (Fig. 2C ). This pattern of binding was similar to that previously observed for the binding of CV-N to the SU of HIV (gp120) by the same assays (4). Additional studies revealed that addition of a free highmannose oligosaccharide (oligomannose-8 [Man-8]) with the same ␣(1-2)-linked mannose structures present as terminal sugars on high-mannose N-linked glycans dramatically reduced the amount of CV-N/SU binding (Fig. 2D) . This suggests that, as previously observed for HIV gp120 (31), CV-N interacts with the SU domain via these mannose structures present on N-linked glycans.
This study is, to our knowledge, the first to present evidence for different lectin susceptibilities for individual viruses within the same genus. CV-N has previously displayed broad-spectrum activity against multiple strains of both influenza virus A and B (8) . Grouping the gammaretroviruses by their susceptibility to inhibition by CV-N mirrors what is already known from phylogenetic analyses about how closely related their Env sequences are: FeLV Env and the polytropic, amphotropic, and xenotropic MLV Envs cluster together, ecotropic MLV Env is less closely related to the other MLVs and FeLV than they are to one another, and Envs of GaLV and KoRV cluster together and are more distantly related to the others (32, 33) .
The observation that CV-N inhibits some but not all gammaretroviruses prompted us to compare the predicted N-glycosylation sites of the viruses. This comparison identified three glycosylation sites (amino acids [aa] 10, 25, and 301 of the reference FeLV; designated sites 1, 2, and 3) present in the viruses strongly inhibited by CV-N and absent in the viruses resistant to CV-N (Fig. 3) . Ecotropic MoMLV, which has intermediate susceptibility to CV-N inhibition, has one of these three sites. Another glycosylation site (aa 345 in FeLV; designated site 4) is present in MoMLV, GaLV, and KoRV and absent in the viruses strongly inhibited by CV-N. These differences suggest that the susceptibility of the gammaretroviruses to CV-N reflects the ability of this lectin to bind at one or more of these glycosylation sites. Sites 1 and 2 lie within the gammaretroviral receptor binding domain region (RBD) (34, 35) within close proximity to residues previously identified as critical for Env function. Site 1 is 4 residues downstream of a histidine residue within the motif PHQ, which has been shown to be critical for fusion of gammaretroviruses to their target cells (36) (37) (38) . Site 2 is within 30 aa of variable region A (VRA), which for both FeLV and MLVs has been shown to contain residues sufficient for receptor binding. The HTLVs, which are resistant to inhibition by CV-N, also lack any glycosylation sites in this region (39) . The proximity of sites 1 and 2 to regions of SU critical for entry suggests that they are the most likely to determine susceptibility to CV-N inhibition. In addition, since for certain MLVs and FeLVs the C-terminal domain of SU is important for postbinding events involved in entry, sites 3 and 4 may contribute to inhibition either by binding CV-N (for site 3) or by blocking the ability of CV-N to bind to a nearby glycosylation site (for site 4).
Despite the presence of several effective vaccines, FeLV is still a major cause of morbidity and mortality in domestic cats and certain wild cats, including the Florida puma (40), Namibian cheetahs (41), the Iberian lynx (42) , and several other species (43) . No treatment described to date has resulted in a cure or complete virus elimination from infected animals (44) The observation that CV-N inhibits replication of FeLV in vitro raises the possibility that CV-N, or a derivative of this lectin, may help to control replication of this virus.
Although reports of enhanced expression of T cell activation markers in peripheral blood mononuclear cells exposed to CV-N in vitro have led to questions about the safety of this lectin (45) , later studies observed low levels of proliferation, and no toxicity, in human T cells exposed to high concentrations of CV-N (46). Moreover, no evidence of inflammation was observed in in vivo studies in which CV-N expressed by Lactobacillus blocked vaginal transmission of SHIV in macaques (20) . These studies suggest that CV-N and derivatives are good candidates for future antiviral therapies.
